Vanflyta Европейски съюз - исландски - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - kyrningahvítblæði, mergbólga - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Seretide Innöndunarduft, afmældir skammtar 50/100 míkróg/skammt Исландия - исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

seretide innöndunarduft, afmældir skammtar 50/100 míkróg/skammt

glaxosmithkline pharma a/s - salmeterolum xínafóat; fluticasonum própíónat - innöndunarduft, afmældir skammtar - 50/100 míkróg/skammt

Seretide Innöndunarduft, afmældir skammtar 50/250 míkróg/skammt Исландия - исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

seretide innöndunarduft, afmældir skammtar 50/250 míkróg/skammt

glaxosmithkline pharma a/s - fluticasonum própíónat; salmeterolum xínafóat - innöndunarduft, afmældir skammtar - 50/250 míkróg/skammt

Seretide Innöndunarduft, afmældir skammtar 50/500 míkróg/skammt Исландия - исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

seretide innöndunarduft, afmældir skammtar 50/500 míkróg/skammt

glaxosmithkline pharma a/s - fluticasonum própíónat; salmeterolum xínafóat - innöndunarduft, afmældir skammtar - 50/500 míkróg/skammt